As of 2026-01-08, the Relative Valuation of Fulcrum Therapeutics Inc (FULC) is (11.73) USD. This relative valuation is based on P/E multiples. With the latest stock price at 9.98 USD, the upside of Fulcrum Therapeutics Inc based on Relative Valuation is -217.6%.
The range of the Relative Valuation is (8.58) - (12.08) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 10.7x - 16.4x | 14.4x |
| Forward P/E multiples | 11.6x - 19.1x | 17.5x |
| Fair Price | (8.58) - (12.08) | (11.73) |
| Upside | -185.9% - -221.1% | -217.6% |
| Date | P/E |
| 2026-01-02 | -14.82 |
| 2025-12-31 | -15.35 |
| 2025-12-30 | -15.39 |
| 2025-12-29 | -16.27 |
| 2025-12-26 | -15.72 |
| 2025-12-24 | -16.30 |
| 2025-12-23 | -16.00 |
| 2025-12-22 | -17.35 |
| 2025-12-19 | -16.67 |
| 2025-12-18 | -16.50 |
| 2025-12-17 | -16.40 |
| 2025-12-16 | -16.97 |
| 2025-12-15 | -17.54 |
| 2025-12-12 | -17.64 |
| 2025-12-11 | -17.37 |
| 2025-12-10 | -18.73 |
| 2025-12-09 | -19.82 |
| 2025-12-08 | -17.63 |
| 2025-12-05 | -12.08 |
| 2025-12-04 | -11.89 |
| 2025-12-03 | -12.30 |
| 2025-12-02 | -12.15 |
| 2025-12-01 | -13.40 |
| 2025-11-28 | -14.85 |
| 2025-11-26 | -15.36 |
| 2025-11-25 | -15.66 |
| 2025-11-24 | -15.93 |
| 2025-11-21 | -15.32 |
| 2025-11-20 | -15.01 |
| 2025-11-19 | -15.62 |
| 2025-11-18 | -13.21 |
| 2025-11-17 | -13.10 |
| 2025-11-14 | -11.74 |
| 2025-11-13 | -11.93 |
| 2025-11-12 | -11.35 |
| 2025-11-11 | -11.06 |
| 2025-11-10 | -10.41 |
| 2025-11-07 | -10.36 |
| 2025-11-06 | -10.38 |
| 2025-11-05 | -10.68 |
| 2025-11-04 | -11.36 |
| 2025-11-03 | -12.24 |
| 2025-10-31 | -11.88 |
| 2025-10-30 | -11.67 |
| 2025-10-29 | -12.70 |
| 2025-10-28 | -13.57 |
| 2025-10-27 | -13.10 |
| 2025-10-24 | -12.51 |
| 2025-10-23 | -12.15 |
| 2025-10-22 | -12.27 |